INSP vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
INSP vs LLY: Head-to-Head Comparison
This page compares Inspire Medical Systems, Inc. (INSP) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.